The global industry for tardive dyskinesia treatment is witnessing significant development. This movement is driven by a increasing prevalence of tardive dyskinesia, coupled with advances in treatment approaches. The market is segmented by various variables, including medication types, distribution channels, and territories. Key stakeholders in the